Alessandro Gonfiotti1, Massimo O Jaus1, Daniel Barale1, Silvia Baiguera2, Camilla Comin3, Federico Lavorini4, Giovanni Fontana4, Oriol Sibila5, Giovanni Rombolà6, Philipp Jungebluth2, Paolo Macchiarini7. 1. Department of General Thoracic and Regenerative Surgery, University Hospital Careggi, Florence, Italy. 2. Advanced Center for Translational Regenerative Medicine, Division of Ear, Nose, and Throat, Karolinska Institutet, Huddinge, Stockholm, Sweden. 3. Division of Pathological Anatomy, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy. 4. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. 5. Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain. 6. Department of Biomedicine, University Hospital Careggi, Florence, Italy. 7. Advanced Center for Translational Regenerative Medicine, Division of Ear, Nose, and Throat, Karolinska Institutet, Huddinge, Stockholm, Sweden. Electronic address: paolo.macchiarini@ki.se.
Abstract
BACKGROUND: In 2008, the first transplantation of a tissue-engineered trachea in a human being was done to replace an end-staged left main bronchus with malacia in a 30-year-old woman. We report 5 year follow-up results. METHODS: The patient was followed up approximately every 3 months with multidetector CT scan and bronchoscopic assessment. We obtained mucosal biopsy samples every 6 months for histological, immunohistochemical, and electron microscopy assessment. We also assessed quality of life, respiratory function, cough reflex test, and production and specificity of recipient antibodies against donor human leucocyte antigen. FINDINGS: By 12 months after transplantation, a progressive cicatricial stenosis had developed in the native trachea close to the tissue-engineered trachea anastomosis, which needed repeated endoluminal stenting. However, the tissue-engineered trachea itself remained open over its entire length, well vascularised, completely re-cellularised with respiratory epithelium, and had normal ciliary function and mucus clearance. Lung function and cough reflex were normal. No stem-cell-related teratoma formed and no anti-donor antibodies developed. Aside from intermittent bronchoscopic interventions, the patient had a normal social and working life. INTERPRETATION: These clinical results provide evidence that a tissue-engineering strategy including decellularisation of a human trachea, autologous epithelial and stem-cell culture and differentiation, and cell-scaffold seeding with a bioreactor is safe and promising. FUNDING: European Commission, Knut and Alice Wallenberg Foundation, Swedish Research Council, ALF Medicine.
BACKGROUND: In 2008, the first transplantation of a tissue-engineered trachea in a human being was done to replace an end-staged left main bronchus with malacia in a 30-year-old woman. We report 5 year follow-up results. METHODS: The patient was followed up approximately every 3 months with multidetector CT scan and bronchoscopic assessment. We obtained mucosal biopsy samples every 6 months for histological, immunohistochemical, and electron microscopy assessment. We also assessed quality of life, respiratory function, cough reflex test, and production and specificity of recipient antibodies against donorhuman leucocyte antigen. FINDINGS: By 12 months after transplantation, a progressive cicatricial stenosis had developed in the native trachea close to the tissue-engineered trachea anastomosis, which needed repeated endoluminal stenting. However, the tissue-engineered trachea itself remained open over its entire length, well vascularised, completely re-cellularised with respiratory epithelium, and had normal ciliary function and mucus clearance. Lung function and cough reflex were normal. No stem-cell-related teratoma formed and no anti-donor antibodies developed. Aside from intermittent bronchoscopic interventions, the patient had a normal social and working life. INTERPRETATION: These clinical results provide evidence that a tissue-engineering strategy including decellularisation of a human trachea, autologous epithelial and stem-cell culture and differentiation, and cell-scaffold seeding with a bioreactor is safe and promising. FUNDING: European Commission, Knut and Alice Wallenberg Foundation, Swedish Research Council, ALF Medicine.
Authors: Johannes C Kutten; David McGovern; Christopher M Hobson; Sarah A Luffy; Alejandro Nieponice; Kimimasa Tobita; Richard J Francis; Susan D Reynolds; Jeffrey S Isenberg; Thomas W Gilbert Journal: Tissue Eng Part A Date: 2014-09-12 Impact factor: 3.845
Authors: Ahmed A Abouarab; Hany H Elsayed; Hussein Elkhayat; Ahmed Mostafa; David C Cleveland; Ahmed El Nori Journal: Ann Thorac Cardiovasc Surg Date: 2017-02-23 Impact factor: 1.520
Authors: Philipp Jungebluth; Johannes C Haag; Sebastian Sjöqvist; Ylva Gustafsson; Antonio Beltrán Rodríguez; Costantino Del Gaudio; Alessandra Bianco; Ivar Dehnisch; Per Uhlén; Silvia Baiguera; Greg Lemon; Mei Ling Lim; Paolo Macchiarini Journal: Nat Protoc Date: 2014-08-14 Impact factor: 13.491
Authors: Liping Zhao; Sumati Sundaram; Andrew V Le; Angela H Huang; Jiasheng Zhang; Go Hatachi; Arkadi Beloiartsev; Michael G Caty; Tai Yi; Katherine Leiby; Ashley Gard; Mehmet H Kural; Liqiong Gui; Kevin A Rocco; Amogh Sivarapatna; Elizabeth Calle; Allison Greaney; Luca Urbani; Panagiotis Maghsoudlou; Alan Burns; Paolo DeCoppi; Laura E Niklason Journal: Tissue Eng Part A Date: 2016-09 Impact factor: 3.845